精選課程
內科用藥
The New Era of HER2-Positive Metastatic Breast Cancer Treatment
積分登錄期間
2023/03/17 17:00 - 2023/04/18 00:00
積分登錄已結束
課程開放閱讀期間
2023/03/17 17:00 - 2025/03/18 00:00
認證積分
專業 1.0
課程開放對象
醫師會員、部分公司會員、網路會員、指定名單
課程介紹
The clinical outcome of HER2+ metastatic breast cancer patients has improved significantly over the past decade, due to the development of various anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors, and the novel antibody-drug conjugates (ADCs). This lecture aims to provide a recap of the historical development of anti-HER2 treatment and how breakthrough treatment establishes the new standard of care for HER2+ metastatic breast cancer and extends patient survival once again.